Form 990 for tax year 2023
Filed by OVARIAN CANCER RESEARCH FUND INC.
This return was superseded by a later amendment. matched by us It is kept because history is preserved rather than replaced.
What the amendment changed
Compared with the latest return for 2023 , filed 13 November 2025. matched by us Only the return's totals, a 990-PF's accounting method and the names listed in Part VII (Part VIII on a 990-PF) are compared. We relate returns by organization, tax year and form, and order them by each return's own timestamp; the filer's own "amended return" checkbox is a separate fact.
Those are the same on the two returns, so the amendment changed something else.
Totals
- Total revenue
- $13,442,515
- Total expenses
- $13,752,760
- Contributions and grants received
- $11,556,311
- Grants paid
- $8,117,910
- Program service revenue
- $438,937
- Investment income
- $1,447,267
- Other revenue
- $0
- Total assets, end of year
- $39,203,357
- Total liabilities, end of year
- $14,720,293
- Net assets or fund balances, end of year
- $24,483,064
- Program services expenses (Part IX)
- $11,116,441
- Management and general expenses
- $1,220,617
- Fundraising expenses
- $1,415,702
- Program service expenses (Part III)
- $11,116,441
Program services were 80.8% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$1,160,499
-
1f · All other contributions, gifts and grants
$10,395,812
-
1g · Noncash contributions included above
$2,797,584
-
2a · Program service revenue: CONFERENCE
total $438,937 · related or exempt $438,937
-
3 · Investment income
total $1,095,100 · excluded $1,095,100
-
7a · Gross sales of assets other than inventory
securities $24,562,455
-
7b · Less cost or other basis and sales expenses
securities $24,210,288
-
7c · Gain or loss
securities $352,167
-
7d · Net gain or loss
total $352,167 · excluded $352,167
-
8a · Fundraising events: gross income
$145,898
-
8a · Fundraising events: contributions included on line 1c
$1,160,499
-
8b · Fundraising events: direct expenses
$145,898
-
8c · Net income from fundraising events
total $0
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $7,397,910 · program services $7,397,910
-
3 · Grants to foreign organizations and individuals
total $720,000 · program services $720,000
-
5 · Compensation of officers, directors and key employees
total $576,063 · program services $247,748 · management and general $241,887 · fundraising $86,428
-
7 · Other salaries and wages
total $1,887,757 · program services $983,575 · management and general $246,307 · fundraising $657,875
-
8 · Pension plan contributions
total $57,486 · program services $30,017 · management and general $6,823 · fundraising $20,646
-
9 · Other employee benefits
total $358,801 · program services $185,282 · management and general $56,396 · fundraising $117,123
-
10 · Payroll taxes
total $184,609 · program services $92,726 · management and general $35,344 · fundraising $56,539
-
11b · Fees: legal
total $40,512 · management and general $40,512
-
11c · Fees: accounting
total $83,213 · management and general $83,213
-
11f · Fees: investment management
total $78,481 · management and general $78,481
-
11g · Fees: other
total $637,844 · program services $423,783 · management and general $214,061
-
12 · Advertising and promotion
total $103,007 · program services $51,503 · management and general $19,572 · fundraising $31,932
-
13 · Office expenses
total $303,836 · program services $79,546 · management and general $41,034 · fundraising $183,256
-
14 · Information technology
total $277,972 · program services $139,621 · management and general $53,218 · fundraising $85,133
-
16 · Occupancy
total $156,400 · program services $78,558 · management and general $29,942 · fundraising $47,900
-
17 · Travel
total $56,824 · program services $46,336 · management and general $10,488
-
19 · Conferences, conventions and meetings
total $287,193 · program services $287,193
-
23 · Insurance
total $18,366 · program services $9,225 · management and general $3,516 · fundraising $5,625
-
24a · Other expenses: GENETIC TESTING
total $285,602 · program services $285,602
-
24b · Other expenses: MISCELLANEOUS
total $103,750 · program services $52,112 · management and general $19,863 · fundraising $31,775
-
24c · Other expenses: CREDIT CARD CHARGES
total $87,992 · fundraising $87,992
-
24d · Other expenses: BANK FEES
total $19,480 · management and general $19,480
-
24e · All other expenses
total $29,662 · program services $5,704 · management and general $20,480 · fundraising $3,478
Balance sheet
Part X, book values.
-
2 · Savings and temporary cash investments
beginning of year $7,221,319 · end of year $3,782,283
-
4 · Accounts receivable
beginning of year $6,857,210 · end of year $669,631
-
9 · Prepaid expenses and deferred charges
beginning of year $72,866 · end of year $112,347
-
10a · Land, buildings and equipment: cost or other basis
$223,290
-
10b · Land, buildings and equipment: accumulated depreciation
$220,915
-
10c · Land, buildings and equipment, net
beginning of year $14,449 · end of year $2,375
-
11 · Investments: publicly traded securities
beginning of year $22,022,779 · end of year $34,459,485
-
15 · Other assets
beginning of year $1,470,465 · end of year $177,236
-
17 · Accounts payable and accrued expenses
beginning of year $196,109 · end of year $247,245
-
18 · Grants payable
beginning of year $13,020,131 · end of year $14,388,180
-
25 · Other liabilities
beginning of year $1,612,582 · end of year $84,868
-
27 · Net assets without donor restrictions
beginning of year $20,616,851 · end of year $13,689,736
-
28 · Net assets with donor restrictions
beginning of year $2,213,415 · end of year $10,793,328
Mission and programs · 2023
Mission
OVARIAN CANCER RESEARCH ALLIANCE (OCRA) IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES.
Activities or mission (Part I)
SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT
-
OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES. OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. EACH YEAR THERE WILL BE OVER 19,000 NEW CASES OF OVARIAN CANCER IN THE UNITED STATES, AND APPROXIMATELY 14,000 WOMEN WILL DIE OF THE DISEASE. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN AND GYNECOLOGIC CANCER COMMUNITIES. SINCE 1998, OCRA HAS AWARDED 418 GRANTS FOR OVARIAN AND RELATED CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 98 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $122 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN AND RELATED CANCERS TO DETERMINE THE ORIGINS, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND EFFECTIVE IMMUNOTHERAPY TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, PREVENTING RECURRENCE AND METASTASIS, AND ENHANCE PATIENTS' QUALITY OF LIFE. FINALLY,OCRA LAUNCHED A NEW GRANT - HEALTH EQUITY RESEARCH GRANT AND AWARDED 3 IN ITS FIRST YEAR. THESE GRANTS WILL FOCUS ON IMPROVING HEALTH EQUITY IN THE GYNECOLOGIC CANCER SPACE.ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE: SHOWN THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; HELPED EXPLAIN RESISTANCE TO CHEMOTHERAPY; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; EXPLORED THE ROLE OF ESTROGEN IN ANTI-TUMOR IMMUNITY; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; IDENTIFIED A NEW THERAPEUTIC STRATEGY FOR CLEAR CELL OVARIAN CANCER; SHOWN HOW A PARP/IMMUNE THERAPY COMBO SHOWS PROMISE; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; CONFIRMED GENERIC HEART MEDICATION CAN PROLONG SURVIVAL IN OVARIAN CANCER PATIENTS; SHED LIGHT ON HOW OVARIAN CANCER GROWS; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; FOUND THAT A SUBSET OF IMMUNE CELLS PROMOTE TUMOR GROWTH; CLARIFIED WHICH CELL LINES ARE THE BEST FIT FOR USE IN OVARIAN CANCER RESEARCH; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED AREAS OF THE HUMAN GENOME THAT ARE LINKED TO INCREASED RISK FOR OVARIAN CANCER; EVALUATED NEW EXPERIMENTAL MODELS TO ADVANCE OVARIAN CANCER RESEARCH; REVEALED HOW COMBINING TARGETED AGENTS IS EFFECTIVE; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; STUDIED MACROPHAGES TO IMPROVE TREATMENT; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER; USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC; DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186); FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL; AND SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK.IN 2023 ALONE, OCRA RESEARCHERS: IDENTIFIED A MOLECULE THAT COULD BE A KEY TO IMPROVING IMMUNE RESPONSE AGAINST OVARIAN CANCER; IDENTIFIED RNA-BINDING PROTEIN GENES AS ANOTHER POTENTIAL SOURCE OF HEREDITARY CANCERS, IN ADDITION TO MORE WELL-KNOWN GENES LIKE BRCA 1/2; SET OUT TO UNDERSTAND HOW CANCER SPREADS AND HOW CANCER CELLS RELY ON/DEPLOY ENERGY SOURCES LIKE SUGAR AND FAT TO SURVIVE TO FIND BETTER TREATMENTS; HIGHLIGHTED THE NEED FOR INDIVIDUAL ASSESSMENT OF COMPLEX VARIANTS TO CORRECTLY IDENTIFY INDIVIDUALS AT RISK; SOUGHT TO UNDERSTAND WHY CERTAIN OVARIAN CANCER CELLS RESIST OLAPARIB TREATMENT, AND DISCOVERED THAT INTRODUCING A SECOND DRUG (MIFEPRISTONE) WHILE TARGETING CERTAIN CELLS (POLYPLOID GIANT CANCER CELLS) MAY OFFER A SOLUTION; DISCOVERED A NEW APPROACH TO IMMUNOTHERAPY THAT OVERCOMES SOME OF THE CHALLENGES OF TREATING OVARIAN CANCER; IDENTIFIED A PREVIOUSLY UNKNOWN CHEMORESISTANT PATHWAY IN HGSC WHICH LED TO WORKING ON A NEW THERAPY TO OVERCOME THIS; PROVIDED AN OVERVIEW OF POTENTIAL THERAPEUTIC STRATEGIES THAT OBSTRUCT PLATELETS' PROTUMOR EFFECTS BY REPROGRAMMING THE TUMOR MICROENVIRONMENT; FOUND THAT MESOTHELIAL CELLS ARE IMPORTANT TO THE INITIAL STAGES OF OVARIAN CANCER GROWTH IN THE ABDOMINAL CAVITY; PROVIDED A NEW THERAPEUTIC STRATEGY TO OVERCOME TME-MEDIATED RESISTANCE TO PARPI ; SHED NEW LIGHT ON HOW THE MOST COMMON SUBTYPE OF OVARIAN CANCER DEVELOPS AND METASTASIZES, BY IDENTIFYING A KEY MOLECULE THAT ALLOWS MALIGNANCIES IN THE FALLOPIAN TUBE TO MIGRATE TO THE OVARIES AND CONTINUE TO GROW; AND UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE THAT CAN HELP EXPLAIN WHY OVARIAN CANCERS HAVE BEEN RESISTANT TO IMMUNOTHERAPY TO DATE. EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG.
Expenses $8,675,579 · Grants $8,117,910
-
EACH YEAR, OCRA BRINGS TOGETHER OVARIAN CANCER PATIENTS, SURVIVORS AND CAREGIVERS AT THE OVARIAN CANCER NATIONAL CONFERENCE, A THREE DAY-LONG EVENT FILLED WITH INFORMATIONAL SESSIONS FEATURING EXPERT SPEAKERS, FUN AND COMMUNITY. MORE THAN 605 PEOPLE FROM ALL AROUND THE WORLD COME TOGETHER VIRTUALLY FOR THIS EVENT. THE SPIRIT OF UNITY AND HOPE IS ALWAYS STRONG AND ATTENDEES CAN LEARN MORE ABOUT THEIR DIAGNOSIS, TREATMENT, AND SURVIVORSHIP. SESSIONS FEATURE TOP OVARIAN CANCER EXPERTS WHO GENEROUSLY GIVE OF THEIR TIME, PRESENTING THE LATEST IN TREATMENTS, RESEARCH, MANAGING RECURRENCE, GENETICS, NUTRITION, CARETAKER AND SUPPORTER CARE, SUPPORT FOR YOUNG WOMEN, ADVOCACY, AND SO MUCH MORE.
Expenses $586,412 · Revenue $438,937
-
BEYOND OUR CONFERENCE, OCRA HAS ADDITIONAL PATIENT EDUCATION AND SUPPORT PROGRAMS AND ENGAGES IN ADVOCACY ON BEHALF OF WOMEN WITH GYNECOLOGIC CANCERS. OUR WEBSITE IS A COMPREHENSIVE SOURCE OF EDUCATIONAL INFORMATION, AND THROUGHOUT THE COURSE OF THE YEAR WE HOLD A SERIES OF FREE, EDUCATIONAL WEBINARS ON A RANGE OF TOPICS RELATED TO THE LATEST RESEARCH, TREATMENT, AND SURVIVORSHIP. OCRA'S PATIENT-SUPPORT LINE IS STAFFED BY OUR SOCIAL WORK TEAM DURING BUSINESS HOURS MONDAY THROUGH FRIDAY AND IS AVAILABLE TO ANYONE SEEKING INFORMATION, SUPPORT, PATIENT NAVIGATION, OR RESOURCE REFERRALS (MEDICAL ADVICE IS NOT PROVIDED). OUR WOMAN TO WOMAN PROGRAM IS A PEER-TO-PEER SUPPORT PROGRAM FOR WOMEN WITH GYNECOLOGIC CANCER. OCRA OFFERS BOTH A NATIONAL WOMAN TO WOMAN PROGRAM AND PROVIDES FINANCIAL SUPPORT TO HELP HOSPITALS AND OTHER ORGANIZATIONS START LOCAL WOMAN TO WOMAN PROGRAMS, WHICH ARE NOW AT MORE THAN 24 SITES ACROSS THE COUNTRY. OUR STAYING CONNECTED SUPPORT SERIES, WHICH LAUNCHED IN 2020, NOW OFFERS FOUR WEEKLY WORKSHOPS AND THREE MONTHLY WORKSHOPS WHICH ENABLES ALL IMPACTED BY OVARIAN OR RELATED GYNECOLOGIC CANCERS A WAY TO LEARN, SHARE, AND CONNECT. OUR ARTS PROGRAM, EXPRESS YOURSELF, OFFERS A COMBINATION OF THERAPEUTIC ARTS, POETRY, AND COMMUNITY BUILDING ACTIVITIES. OCRA PARTNERS WITH INSPIRE.COM TO OFFER AN ONLINE SUPPORT COMMUNITY THAT HAS OVER 80,000 MEMBERS WORLD-WIDE. OCRA IS COMMITTED TO ENCOURAGING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS TO FOCUS ON THE CRITICAL NEEDS OF THOSE DIAGNOSED WITH GYNECOLOGIC CANCER, WHETHER AT BENCH OR BEDSIDE. THROUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT, WE ACCEPT TOP MASTER OF SOCIAL WORK CANDIDATES TO TRAIN WITH OUR LICENSED CLINICAL SOCIAL WORKERS TO ADDRESS THE SPECIFIC NEEDS OF OUR COMMUNITY. OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. EACH YEAR, MORE THAN 1,000 SURVIVOR VOLUNTEERS DELIVERED PRESENTATIONS AT 405+ SCHOOLS IN 41 STATES (AS WELL AS UK, CANADA AND AUSTRALIA), AND REACH OVER 10,000 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS ENSURE THE NEXT GENERATION OF HEALTH CARE PROVIDERS UNDERSTAND BASIC FACTS ABOUT THE DISEASE, ARE AWARE OF RISK FACTORS, AND CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS. OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES FOR EVERYONE TOUCHED BY GYNECOLOGIC CANCER . EACH YEAR OCRA PLAYS A CRITICAL ROLE IN HELPING TO SECURE MORE THAN $200 MILLION IN FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION. IN ADDITION, OUR GROWING ADVOCATE LEADER PROGRAM TRAINS MEMBERS OF THE GYNECOLOGIC CANCER COMMUNITY TO RAISE AWARENESS THROUGH NEWS ARTICLES AND OUTREACH, DEVELOP RELATIONSHIPS WITH THEIR ELECTED OFFICIALS, AND FIGHT FOR INCREASED FUNDING FOR GYNECOLOGIC CANCER RESEARCH THROUGHOUT THE COUNTRY.
Expenses $1,854,450
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
John OrricoJOHN ORRICO
CHAIR
- Total calculated
- $0
- Hours/week
- 3
-
Matthew Neal MillerMATTHEW NEAL MILLER
VICE PRESIDENT
- Total calculated
- $0
- Hours/week
- 2
-
Mark TessarMARK TESSAR
TREASURER
- Total calculated
- $0
- Hours/week
- 2
-
Robin S CohenROBIN S COHEN
SECRETARY
- Total calculated
- $0
- Hours/week
- 2
-
Jeannette ChangJEANNETTE CHANG
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Dr Carmel J CohenDR CARMEL J COHEN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Mei-Li Da Silva Vint EsqMEI-LI DA SILVA VINT ESQ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Andrew FeuersteinANDREW FEUERSTEIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Carol J HamiltonCAROL J HAMILTON
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
John W Hansbury EsqJOHN W HANSBURY ESQ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Caroline HirschCAROLINE HIRSCH
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Veronica JordanVERONICA JORDAN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Thomas C LiebmanTHOMAS C LIEBMAN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Dana L Mark EsqDANA L MARK ESQ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Ylain G MayerYLAIN G MAYER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Chris NewcombCHRIS NEWCOMB
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Lisa SchreiberLISA SCHREIBER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Elle Simone ScottELLE SIMONE SCOTT
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Christopher TilberisCHRISTOPHER TILBERIS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Audra L MoranAUDRA L MORAN
PRESIDENT & CEO
- Total calculated
- $345,710
- From this org
- $312,816
- From related orgs
- $0
- Other
- $32,894
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $312,816
- Bonus
- $0
- Other
- $0
- Deferred
- $12,862
- Nontaxable benefits
- $20,032
- Filer's total
- $345,710
-
Bibi AliBIBI ALI
CHIEF FINANCIAL OFFICER
- Total calculated
- $230,353
- From this org
- $202,842
- From related orgs
- $0
- Other
- $27,511
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $202,842
- Bonus
- $0
- Other
- $0
- Deferred
- $7,566
- Nontaxable benefits
- $19,945
- Filer's total
- $230,353
-
Jonathan ZeidmanJONATHAN ZEIDMAN
CHIEF DEVELOPMENT OFFICER
- Total calculated
- $233,344
- From this org
- $204,750
- From related orgs
- $0
- Other
- $28,594
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $204,750
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $28,594
- Filer's total
- $233,344
-
Sarah DefeoSARAH DEFEO
CHIEF PROGRAM OFFICER
- Total calculated
- $220,226
- From this org
- $183,750
- From related orgs
- $0
- Other
- $36,476
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $183,750
- Bonus
- $0
- Other
- $0
- Deferred
- $7,350
- Nontaxable benefits
- $29,126
- Filer's total
- $220,226
-
Tracy MooreTRACY MOORE
VP - SUPPORT & EDUCATION
- Total calculated
- $178,479
- From this org
- $152,500
- From related orgs
- $0
- Other
- $25,979
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $152,500
- Bonus
- $0
- Other
- $0
- Deferred
- $6,100
- Nontaxable benefits
- $19,879
- Filer's total
- $178,479
-
Nicole WargoNICOLE WARGO
VP - PHILANTHROPIC PARTNER
- Total calculated
- $154,139
- From this org
- $128,823
- From related orgs
- $0
- Other
- $25,316
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $128,823
- Bonus
- $0
- Other
- $0
- Deferred
- $5,153
- Nontaxable benefits
- $20,163
- Filer's total
- $154,139
-
Chad RamseyCHAD RAMSEY
VP - POLICY
- Total calculated
- $143,642
- From this org
- $119,107
- From related orgs
- $0
- Other
- $24,535
- Hours/week
- 40
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Form 990 of other organizations
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
MD ANDERSON CANCER CENTER
$1,350,000
RESEARCH GRANT
-
$1,333,314
RESEARCH GRANT
-
RESEARCH GRANT
-
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
$888,314
RESEARCH GRANT
-
$650,000
RESEARCH GRANT
-
RESEARCH GRANT
-
RESEARCH GRANT
-
RESEARCH GRANT
-
$450,000
RESEARCH GRANT
-
RESEARCH GRANT
The 10 largest by cash amount. The API serves every itemized grant.
Fundraising and gaming
From Schedule G of this return, as filed.
- Had an agreement with a professional fundraiser (line 2a)
- Not answered
Fundraising events (Part II)
Part II has at most four columns: the two largest events, the rest together, and the total.
| Line | Event 1 OVARIAN CYCLE | Other events 2 events | Total |
|---|---|---|---|
| Gross receipts (line 1) | $178,798 | $1,127,599 | $1,306,397 |
| Less contributions (line 2) | $159,380 | $1,001,119 | $1,160,499 |
| Gross income (line 3) | $19,418 | $126,480 | $145,898 |
| Cash prizes (line 4) | — | — | — |
| Noncash prizes (line 5) | — | — | — |
| Rent and facility costs (line 6) | — | — | — |
| Food and beverages (line 7) | — | — | — |
| Entertainment (line 8) | — | — | — |
| Other direct expenses (line 9) | — | — | — |
- Direct expenses (line 10)
- —
- Net income (line 11)
- $145,898
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $720,000
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| NORTH AMERICA | 0 | 0 | AWARDING OF GRANTS | AWARDING OF RESEARCH GRANTS | $720,000 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| NORTH AMERICA | $450,000 | — | $0 | — | — |
| NORTH AMERICA | $270,000 | — | $0 | — | — |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- —
- Other grantees (Part II line 3)
- 2
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
OVARIAN CANCER NATIONAL ALLIANCE
501(C)(3) · EDUCATION & ADVOCACY · DC · controlled entity
Directly controlled by OVARIAN CANCER RESEARCH FUND INC
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 14 November 2024
- IRS schema version
- 2023v5.1
- Source object
- 202423199349310332
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.